Author(s):
Sruthy Jose, Anukrishna VP, Aarcha K Ajayan, Malavika Gopi, Rohan Rajendran, Meenu Vijayan
Email(s):
meenuvijayan@aims.amrita.edu
DOI:
10.52711/0974-360X.2023.00390 
Address:
Sruthy Jose1, Anukrishna VP1, Aarcha K Ajayan1, Malavika Gopi1, Rohan Rajendran2, Meenu Vijayan3*
1Student, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
2Assistant Professor, Department of Urology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
3Assistant Professor, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 5,
Year - 2023
ABSTRACT:
Background: Despite antimuscarinic treatment options being available as the first line agents for overactive bladder (OAB), there is still a need for distinct treatment approaches to manage its suboptimal response and noncompliance. Mirabegron, a ß3-adrenoceptor agonist, could be a better alternative to antimuscarinics in OAB treatment with a good effectiveness/tolerability balance. Aim: To compare the clinical profile of mirabegron and antimuscarinics in the treatment of overactive bladder. Method: A prospective, observational study was conducted in two groups of patients who received either mirabegron (n=120) or antimuscarinics (n=120) for the treatment of OAB. Effectiveness of the drugs were assessed at baseline, 4 and 8 weeks after the treatment using the Overactive Bladder Symptom Score (OABSS) and International Prostatic Symptom Score (IPSS) questionnaires. The safety assessment was done by measuring the post-void residual (PVR) urine volume and assessing the adverse drug reactions (ADR). The probability and severity of the ADRs were measured using Naranjo scale and Hartwig’s scale respectively. Also a subgroup analysis was carried out to compare the effectiveness of the two drugs in patients with OAB related to benign prostatic hyperplasia (BPH). Results: The overall effectiveness of antimuscarinics and mirabegron was found to be similar, but mirabegron showed better reduction in the daytime frequency (p=0.049). They also differ in safety profile with the overall incidence of adverse events being significantly higher in antimuscarinics group (15.83%) (19/120) than in the mirabegron group group (1.7%) (2/120) (p<0.001). In the patients with OAB related to BPH also, there was a better reduction in the daytime frequency with mirabegron than with antimuscarinics, with overall effectiveness between groups being similar. In addition, mirabegron did not worsen the voiding symptoms and was found to be a better combination with alpha1 blockers than the antimuscarinics in patients with OAB related to BPH. No significant change was there in the PVR values within and between the groups. Conclusion: Mirabegron is a better alternative to antimuscarinics in the treatment of OAB with a distinct effectiveness/tolerability balance especially in patients with OAB related to BPH.
Cite this article:
Sruthy Jose, Anukrishna VP, Aarcha K Ajayan, Malavika Gopi, Rohan Rajendran, Meenu Vijayan. A Comparative Study on the effectiveness and Tolerability of Mirabegron and Antimuscarinics in the treatment of Overactive bladder. Research Journal of Pharmacy and Technology 2023; 16(5):2369-4. doi: 10.52711/0974-360X.2023.00390
Cite(Electronic):
Sruthy Jose, Anukrishna VP, Aarcha K Ajayan, Malavika Gopi, Rohan Rajendran, Meenu Vijayan. A Comparative Study on the effectiveness and Tolerability of Mirabegron and Antimuscarinics in the treatment of Overactive bladder. Research Journal of Pharmacy and Technology 2023; 16(5):2369-4. doi: 10.52711/0974-360X.2023.00390 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-5-49
REFERENCES:
1. Abrams P, Artibani W, Cardozo L, Dmochowski, R, Van Kerrebroek, P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neuronal Urodyn 2009; 28:287.
2. Ubee SS, Manikandan R, Singh G. Medical management of overactive bladder. Indian J Urol 2010; 26:270-8
3. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132-8
4. Miller J, Hoffman E. The causes and consequences of overactive bladder. J Womens Health (Larchmt) 2006; 15:251-60
5. Krishnan S, Nampoothiri V, Vinod K, Vijayan N, Priyavijyakumar, Vijayan M. Study on clinical pharmacists' initiated interventions in geriatric population. RJPBCS 2016 Jul 1;7(4):2952-60.
6. Kobayashi M, Nukui A, Kamai T. Comparative efficacy and tolerability of antimuscarinic agents and the selective β3‐adrenoceptor agonist, mirabegron, for the Treatment of overactive bladder: which is more preferable as an initial treatment?.LUTS 2018;10:158-66.
7. Puneet A, Balagopal N, Ginil K, Georgie M, Sanjeevan KV, Appu T. Correlation of transabdominal ultrasonography and cystoscopy in follow-up of patients with non-muscle invasive bladder cancer. Indian J of Surgical Oncology. 2017 Dec 1;8(4):548-53.
8. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002;60:7-12.
9. Kim SY, Bang W, Choi HG. Analysis of the prevalence and associated factors of overactive bladder in adult Korean men. PLoS One 2017; 12: e0175641.
10. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001;166:550-2.
11. Gotoh M, Homma Y, Yokoyama O, Nishizawa O. Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology 2011;78:768-73.
12. Meyer LE, Brown JN. Tamsulosin for voiding dysfunction in women. Int Urol Nephrol 2012;44:1649-56.
13. Nitti VW , Auerbach S, Martin N, Calhoun A, Lee M, Herschor S.Results of Randomised phase III trial of mirabegron in patients with OAB .J Urol 2013;189: 1388-1395.
14. Otsuka A, Kageyama S, Suzuki T, et al. Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study). Int J Urol 2016;23:1016-1023.
15. Otsuki H, Kosaka T, Nakamura K, Mishima J, Kuwahara Y, Tsukamoto T. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol 2013;45:53-60.
16. Alexandre EC, Kiguti LR, Calmasini FB, et al. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3‐adrenoceptor activation and α1‐adrenoceptor blockade. Br J Pharmacol. 2016;173:415-28.